Arkolith/Insider Trading/VRTX/Form 4

Bunnage Mark E.

EVP, Chief Scientific OfficerVERTEX PHARMACEUTICALS INC / MA (VRTX) · full profile →Form 4 · filed May 19, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$15K
Net Open-Market Flow
-$15K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 15, 2026Sell(S)33$453.45$15K7K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000875320-26-000226) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML